{"filing":{"accession_number":"0001193125-26-347957","cik":"0001841387","ticker":"CADL","company_name":"Candel Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"cadl-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-20260813.htm"},"events":[{"id":27544,"run_id":25113,"accession_number":"0001193125-26-347957","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Candel Therapeutics announced its financial results for the quarter ended June 30, 2026, on August 13, 2026, with the full press release furnished as Exhibit 99.1. The disclosure includes quarterly R\u0026D expenses ($19.8M vs. $7.0M YoY), G\u0026A expenses ($6.9M vs. $4.2M YoY), net loss ($38.9M vs. $4.8M YoY), and cash position ($201.6M), along with operational highlights. This is a standard quarterly earnings release disclosing results of operations and financial condition under Item 2.02.","company_name":"Candel Therapeutics, Inc.","ticker":"CADL","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29124,"accession_number":"0001193125-26-347957","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Candel Therapeutics announced its financial results for the quarter ended June 30, 2026, on August 13, 2026, with the full press release furnished as Exhibit 99.1. The disclosure includes quarterly R\u0026D expenses ($19.8M vs. $7.0M YoY), G\u0026A expenses ($6.9M vs. $4.2M YoY), net loss ($38.9M vs. $4.8M YoY), and cash position ($201.6M), along with operational highlights. This is a standard quarterly earnings release disclosing results of operations and financial condition under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:16:47.229035+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29124,"accession_number":"0001193125-26-347957","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Candel Therapeutics announced its financial results for the quarter ended June 30, 2026, on August 13, 2026, with the full press release furnished as Exhibit 99.1. The disclosure includes quarterly R\u0026D expenses ($19.8M vs. $7.0M YoY), G\u0026A expenses ($6.9M vs. $4.2M YoY), net loss ($38.9M vs. $4.8M YoY), and cash position ($201.6M), along with operational highlights. This is a standard quarterly earnings release disclosing results of operations and financial condition under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:16:47.229035+00:00","company_name":"Candel Therapeutics, Inc.","ticker":"CADL","filing_date":"2026-08-13"}]}